The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InSeaport Therapeutics, a biotech firm founded by PureTech Health, has announced the publication of peer-reviewed research in the prestigious journal Science Translational Medicine regarding its SPT-300 candidate. The study identifies SPT-300 as the first triglyceride-mimetic prodrug to successfully achieve therapeutically relevant drug levels in human subjects. Utilizing the proprietary Glyph platform, the technology enables oral absorption through the lymphatic system, effectively bypassing first-pass metabolism in the liver. This publication serves as a critical scientific validation for the drug delivery platform, which aims to enhance the bioavailability of neuropsychiatric treatments. The successful demonstration of the Glyph platform's capabilities is expected to provide a positive catalyst for the valuation of its parent company, PureTech Health. This milestone underscores the significant potential for developing more effective oral therapies within the global biotechnology sector.